Experimental device tested to control aggressive brain tumor growth
NCT ID NCT03450850
Summary
This study tested a medical device called NOVOTTF-200A in adults with a recurrent, aggressive type of brain tumor called grade 3 astrocytoma. The main goal was to see if the device could help control the tumor's growth for at least six months in patients who had not received a specific prior drug (bevacizumab). Researchers also looked at safety, quality of life, and whether certain genetic markers in the tumor predicted a better response to the device.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, GRADE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, Irvine
Orange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.